Major obstacles for personalized medicine according to pharma companies 2015

This statistic is based on a survey conducted during the 2nd quarter of 2015. It describes major obstacles for developing personalized medicines according to pharmaceutical companies in Asia, Europe, and in the United States. Most of respondents stated that the lack of a regulatory guidance would be the major obstacle for developing personalized medicines.

Major obstacles for developing personalized medicines according to pharmaceutical companies worldwide as of 2015

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

November 2015

Region

North America, Asia, Europe

Survey time period

Q2 2015

Number of respondents

100 senior executives (CEO, CIO, Director of Strategy) in biotechnology and pharmaceuticals companies

Supplementary notes

Original question: "What are the hurdles in developing personalised medicines?" (Please select the most important)

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.